Data Selected for Presentation Highlights Anti-Tumor effects of KRX-0401 (Perifosine)
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the company's lead anti-cancer compound, at the American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado.
Abstracts selected for presentation today, Tuesday, April 21, 2009, are as follows:
Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models.
Author(s): Zhijie Li, Fei Tan, Jenna Tong, Amy McKee, Carol Thiele. National Cancer Inst., Bethesda, MD
Time/location: 8:00 AM - 12:00 PM, Hall B-F, Poster Section 10, # 13
Abstract Summary: In vitro studies in neuroblastoma cell lines indicate that perifosine treatment induced inhibition of Akt phosphorylation, and decreases of cell survival. In vivo studies of perifosine treatment led to significant increases in neuroblastoma tumor bearing mouse survival. In summary, Investigators conclude that the data indicates that as a single agent, perifosine targets activation of Akt in neuroblastoma cells and xenografts, and significantly inhibits tumor growth.
Targeting breast cancer stem cells through inhibition of PI3-K/Akt/B-catenin signaling
Author(s): Korkaya Hasan, Amanda K. Paulson, Max S. Wicha.
Time/location: 3:10 - 3:25 PM, Room 205-207, Colorado Convention Ctr.
Session Title: Cancer Stem Cell Approaches for Identification and Targeting
Abstract Summary: According to In
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved